Perrigo Positioned To Prosper From Potential Amazon OTC Product Play
This article was originally published in The Pink Sheet
Executive Summary
CEO John Hendrickson says Perrigo would work with Amazon to develop its own private label OTC line and would not expect to lose existing customers. At a recent investor conference, he said Amazon’s commitment to the OTC category would help grow the market, not take market share from other firms.
You may also be interested in...
Perrigo Glows From Mucinex Private Label Plan, Starboard Plug
Perrigo plans to introduce two more Mucinex store brand products within six months after a series of manufacturing stumbles, CEO John Hendrickson says. The firm's private label prowess, says activist investor Jeffrey Smith, is insurance that it will grow as e-commerce grows.
Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.
Navigating Amazon: E-Commerce Giant Critical For OTC Drug Sales
As Amazon emerges as the leading search engine for information about consumer packaged goods products, OTC drug and other consumer health product firms should establish a presence, even if they expect not to sell much, says BeeKeeper consultancy's Lynn Graham.